HEMOPHILIA

Hemophilia

Hemophilia studies require precise sample timing, standardized coagulation testing, inhibitor monitoring, and traceable sample logistics. Omega Core Lab supports hemophilia clinical trials through coordinated laboratory, genetic analysis, biorepository, and home-sampling workflows.

Hemophilia Clinical Trial Support

In hemophilia studies, the value of laboratory data comes not only from performing the test, but also from accurate sample timing, standardization of coagulation parameters, inhibitor monitoring, and proper management of the patient journey. Omega Core Lab supports Hemophilia A and Hemophilia B studies through an integrated model covering central laboratory services, genetic analysis, sample management, and home-sampling processes.

From coagulation testing to inhibitor monitoring, genetic confirmation, and sample logistics, we help sponsors build traceable, protocol-aligned workflows for hemophilia studies.

Why is a Specialized Laboratory Approach Required in Hemophilia Studies?

Critical laboratory outputs in hemophilia studies are often highly time-sensitive. Parameters such as Factor VIII (FVIII) and Factor IX (FIX) activity, inhibitor development, pharmacokinetic/pharmacodynamic (PK/PD) evaluations, post-bleeding episode sampling, and response to prophylaxis require strict adherence to protocol-defined time windows. Guidelines from the World Federation of Hemophilia also emphasize the importance of genetic evaluation, extended half-life factor products, and emerging treatment approaches in hemophilia management.

In hemophilia studies, routine safety laboratory assessments and coagulation testing should be planned in an integrated manner. Parameters such as factor activity measurements, activated partial thromboplastin time (aPTT), prothrombin time (PT), complete blood count, and biochemistry are structured according to protocol-defined time points. The goal is to ensure a comparable data flow between clinical events, treatment administration, and laboratory results.

Inhibitor development is one of the most critical complications in hemophilia treatment. The Centers for Disease Control and Prevention (CDC) recommends that individuals with hemophilia or type 3 von Willebrand disease who use factor concentrates should be tested for inhibitors at least once a year. In clinical trials, inhibitor testing schedules, sample stability, laboratory methodology, and reporting language should be standardized from the outset.

Pharmacokinetic/pharmacodynamic (PK/PD) sampling can be critical in studies involving factor replacement products, extended half-life factors, non-factor therapies, and gene therapy. Pre-dose and post-dose time points, trough levels, peak levels, and long-term response monitoring are structured according to the study protocol.

Hemophilia A and Hemophilia B are inherited bleeding disorders associated with the F8 and F9 genes, respectively. Genetic confirmation can be valuable for patient stratification, family history assessment, variant interpretation, and eligibility evaluation in certain study designs. Integration with Omega Genetik can be particularly emphasized in this context.

In hemophilia patients, factors such as frequent visit burden, pediatric populations, limited mobility, or time-sensitive sampling following bleeding episodes make home sampling and mobile team models especially valuable.

Süreç Nasıl Çalışır

Coagulation Testing Coordination

Protocol-aligned sampling and reporting workflows for factor activity, coagulation parameters, and safety laboratory outputs.

Inhibitor and Immunogenicity Workflows

Traceable sample and data management for inhibitor development, anti-drug antibody, and immunogenicity assessments.

Genetic Confirmation and Patient Stratification

Molecular analysis support for F8/F9-related genetic evaluation, family history assessment, and study eligibility processes.

Pharmacokinetic/Pharmacodynamic and Treatment Response Sampling

Time-sensitive sampling support for factor replacement, non-factor therapies, and advanced treatment programs.

Biorepository and Long-Term Follow-up

Secure sample storage and retrieval processes for long-term follow-up, post-gene therapy monitoring, and translational research.

Why Are Our Services Critical in Hemophilia Studies?

In hemophilia studies, laboratory data lies at the core of clinical decision-making and study endpoints. Samples collected at incorrect time points, transported under suboptimal conditions, or analyzed using different methodologies across sites can directly impact the interpretation of factor activity, inhibitor status, and treatment response. For this reason, the Omega Core Lab approach goes beyond test execution; it provides an integrated study partner model that plans, monitors, and documents the entire sample journey from collection to reporting.

Omega Core Lab support in hemophilia studies can be tailored according to study needs and integrated across HelixLab, Omega Genetik, Omega Biorepository, and OmegaCare processes. This structure brings together central laboratory testing, genetic/molecular analysis, long-term sample storage, and home sampling operations under a single coordinated workflow. Existing Core Lab documentation also defines this integrated model across HelixLab, Omega Genetik, biorepository, OmegaCare, and digital solutions.

Planning a Hemophilia Study?

Share your protocol or a summary of your laboratory requirements; we can prepare a study-specific Core Lab scope proposal covering coagulation testing, inhibitor monitoring, genetic analysis, sample timing, and biorepository needs.

Request a Feasibility Call